Sangam Health Care Products Ltd reported an 88.1% decline in net profit to ₹5.33 lakh for the financial year ended March 31, 2026, down from ₹44.96 lakh in the previous year. The company's revenue from operations fell 9.8% to ₹1,123.33 lakh for FY26, compared to ₹1,245.96 lakh in FY25. The decline in profitability was driven by increased employee benefit expenses and other expenses, which rose to ₹228.68 lakh and ₹277.90 lakh respectively.

The Board of Directors approved the audited financial results for the quarter and year ended March 31, 2026, at a meeting held on May 29, 2026. The statutory auditors, M M Reddy & Co., issued an audit report with an unmodified opinion on the standalone annual financial results. The audit was conducted in accordance with the Standards on Auditing specified under section 143(10) of the Companies Act, 2013.

For the quarter ended March 31, 2026, the company reported a net loss of ₹27.89 lakh, contrasting with a net profit of ₹18.76 lakh in the same quarter of the previous year. Revenue for the quarter stood at ₹265.50 lakh, slightly higher than the ₹258.17 lakh recorded in the corresponding period of the prior year. Total expenses for the quarter increased to ₹314.99 lakh from ₹261.02 lakh.

The balance sheet as of March 31, 2026, shows total assets at ₹1,122.13 lakh, a decrease from ₹1,134.46 lakh in the previous year. The company's equity and liabilities reflected a negative total equity of ₹(1,984.94) lakh, primarily due to accumulated losses in reserves and surplus amounting to ₹(3,471.01) lakh. Non-current liabilities stood at ₹2,356.31 lakh, while current liabilities were ₹750.76 lakh.

Cash flow from operating activities for FY26 was positive at ₹2.57 lakh, a significant recovery from the negative cash flow of ₹(275.97) lakh in the previous year. However, the company reported a net decrease in cash and cash equivalents of ₹(5.57) lakh during the year, bringing the closing balance to ₹15.17 lakh. The financial statements were prepared in compliance with the Indian Accounting Standards (Ind AS) and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Financial Performance Summary

Sangam Health Care Products Ltd has filed its quarterly compliance certificate with BSE Limited under SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended March 31, 2026. The certificate, submitted on April 15, 2026, addresses the company's adherence to dematerialization procedures and regulatory requirements.

Compliance Certificate Details

The compliance certificate was submitted under Regulation 74(5) of the SEBI regulations, covering the quarter and year ended March 31, 2026. Managing Director D. Bhagat Reddy (DIN: 07087331) signed the certificate on behalf of the company, confirming compliance with dematerialization processes.

Registrar Confirmation

XL Softech Systems Limited, serving as the company's registrar and transfer agent, provided the underlying confirmation certificate dated April 2, 2026. The registrar confirmed that securities received from depository participants for dematerialization during the quarter ended March 31, 2026 were properly processed and confirmed to the depositories.

The registrar's certificate specifically confirms that:

• Securities received for dematerialization were mutilated and cancelled after due verification
• The name of depositories was substituted in the register of members as registered owners within 30 days
• Securities comprised in the certificates are listed on the stock exchange where earlier issued securities are listed

Regulatory Framework

The compliance certificate references multiple regulatory circulars, including NSDL/CIR/II/5/2019 dated January 25, 2019, CDSL/OPS/RTA/POLCY/2019/14 dated January 25, 2019, and SEBI letter ref no. MRD/DOP2/DSA2/OW/2019/2498/1 dated January 24, 2019. These circulars establish the framework for quarterly compliance reporting by listed companies regarding dematerialization processes.

Corporate Information

Sangam Health Care Products Ltd operates with BSE scrip code 531625. The company maintains its registrar and transfer agent services through XL Softech Systems Limited, based in Hyderabad. The compliance certificate was also copied to Central Depository Services (India) Limited and National Securities Depository Limited, as required under the regulations.